Cost determinants in aggressive non-Hodgkin's lymphoma

Haematologica

Volumn 90, Issue 5, 2005, Pages 661-671

  Van Agthoven, Michel ^a   Sonneveld, Pieter ^a   Verdonck, Leo F ^b   Uyl De Groot, Carin A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antineoplastic combined chemotherapy protocols; Cost and cost analysis; Diffuse large cell lymphoma; Economics; Non Hodgkin's lymphoma

Indexed keywords

ANTIBIOTIC AGENT; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOSTATIC AGENT; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IFOSFAMIDE; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; AGE; AGE DISTRIBUTION; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FEVER; FOLLOW UP; HEALTH CARE COST; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTASIS; NIGHT SWEAT; NONHODGKIN LYMPHOMA; NONPARAMETRIC TEST; PERFORMANCE; PREDICTION; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SYMPTOM; VALIDATION PROCESS; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG COSTS; FEMALE; FEVER; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HEALTH CARE COSTS; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NETHERLANDS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SWEATING; WEIGHT LOSS;

EID: 20344394929     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Visser O, Coebergh JWW, van Dijck JAAM and Siesling S. Incidence of cancer in the Netherlands 1998. Utrecht: Association of Comprehensive Cancer Centers, 2002.
2. Hauke RJ, Armitage JO. A new approach to non-Hodgkin's lymphoma. Intern Med 2000;39:197-208.
3. Zeeb H and Blettner M. [Increasing incidence and mortality or non-Hodgkin lymphomas. An epidemiological review of recent studies on risk factors for non-Hodgkin lymphoma]. Med Klin (Munich) 2001;96:87-100.
4. McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976;38:1484-93.
5. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002-6.
6. van Agthoven M, Sonneveld P, Hagenbeek A and Uyl-de Groot CA. A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma. Hematol J 2003;4: 399-409.
7. Cheson BD. CHOP plus rituximab - balancing facts and opinion. N Engl J Med 2002;346:280-2.
8. Garrison L, Towse A. The drug budget silo mentality in Europe: an overview. Value in Health 2003;6:S1-S9.
9. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's Lymphoma. N Engl J Med 1993;329:987-94.
10. van Agthoven M, Uyl-de Groot CA, Sonneveld P, Hagenbeek A. Economic assessment in the management of non-Hodgkin's lymphoma. Expert Opin Pharmacother 2004;5:2529-48.
11. Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982;49:2112-35.
12. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31: 1860-1.
13. Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MHH, van Oers MHJ, et al. Randomized trial of CHOP versus CHOP plus Granulocyte Colony-Stimulating Factor (G-CSF) in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041-50.
14. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984;44:3643-53.
15. HOVON, iMTA and CBO. Guideline 'non-Hodgkin's lymphoma'. Alphen aan den Rijn: van Zuiden Communications BV. 2004.
16. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. New York/Oxford: Oxford University Press; 1997.
17. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Manual for costing research (in Dutch). Amstelveen: Health Care Board. 2000.
18. Homgren CT, Foster G. Cost accounting: a managerial emphasis. New Jersey: Prentice Hall. 2000.
19. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press. 1996.
20. van Loenen AC. Pharmaceutical Compass 2003. Amstelveen: Health Care Board, 2003.
21. Riteco JA, de Heij LJM, van Luijn JCF, Wolff I. Guidelines for pharmaco-economic studies (in Dutch). Amstelveen: Health Care Board 1999.
22. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000;19:3219-36.
23. Severens JL, De Boo TM, Konst EM. Uncertainty of incremental cost-effectiveness ratios. A comparison of Fieller and bootstrap confidence intervals. Int J Technol Assess Health Care 1999;15: 608-14.
24. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
25. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18:3558-85.
26. Doorduijn JK, Buijt I, van der Holt B, van Agthoven M, Sonneveld P, Uyl-de Groot CA. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica 2004;89:1109-17.
27. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-33.
28. van Agthoven M, Faber LM, Uyl-de Groot CA, Sonneveld P, Verdonck LF, Willemze R, et al. Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma. Eur J Haematol 2002;69:213-20.
29. Kuruvilla J, Cavalcanti R, Keating A, Crump M. Addition of rituximab to CHOP is an attractive strategy as primary therapy for diffuse large B cell lymphoma (DLBCL) in patients age <60 years: an economic analysis. Blood 2004;104:3126.
30. Groot MT, Lugtenburg PJ, Homberger J, Huijgens PC, Uyl-de Groot CA. Cost-effectiveness of rituximab (MabThera®) in diffuse large B-cell lymphoma in the Netherlands. Eur J Haematol 2005;74:194-202.
31. Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology 2004;1:221-36.
32. Berto P, Morsanutto A, Lopatriello S, Martelli M, Muti G, Santini G, et al. Analisi costo-efficacia di rituximab + CHOP versus CHOP in soggetti affetti da linfoma non-Hodgkin aggressive. Pharmacoeconomics - Italian Research Articles 2004;6:151-60.